Funder
National Science Foundation
National Institutes of Health
US Department of Defense
National Cancer Institute
Hyundai Hope On Wheels
Stanford Cancer Institute
Bill and Melinda Gates Foundation
Damon Runyon Cancer Research Foundation
Subject
General Biochemistry, Genetics and Molecular Biology
Reference31 articles.
1. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition;Buchbinder;Am. J. Clin. Oncol.,2016
2. PD-1 and its ligands in tolerance and immunity;Keir;Annu. Rev. Immunol.,2008
3. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy;Hofmann;Eur. J. Cancer,2016
4. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N. Engl. J. Med.,2015
5. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study;McDermott;J. Clin. Oncol.,2016
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献